Oppenheimer downgrades Insulet stock rating on diabetes growth concerns

Oppenheimer downgraded Insulet Corporation (NASDAQ:PODD) to Perform from Outperform due to concerns over its growth outlook after revised guidance. The company lowered its fiscal 2026 U.S. growth forecast, attributing issues to execution challenges in Type 2 diabetes, while Oppenheimer views them as more structural. Despite an earnings beat, the guidance cut overshadowed positive financial results.